Proteins implicated in the increase of adhesivity induced by suberoylanilide hydroxamic acid in leukemic cells

Journal of Proteomics

Volumn 77, Issue , 2012, Pages 406-422

  Grebenova D ^a   Roselova P ^a   Pluskalova M ^a   Halada, P ^b   Rosel D ^c   Suttnar, J ^a   Brodska B ^a   Otevrelova P ^a   Kuzelova K ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adhesion; Cofilin; HDAC inhibitor; PAK; SAHA; Vimentin

Indexed keywords

BUTYRIC ACID; COFILIN; HISTONE DEACETYLASE INHIBITOR; PAXILLIN; PROTEIN 14 3 3; PROTEIN 14 3 3 EPSILON; SERINE; STATHMIN; UNCLASSIFIED DRUG; VIMENTIN; VORINOSTAT;

ANIMAL CELL; ARTICLE; CELL ADHESION; CONTROLLED STUDY; FOCAL ADHESION; HISTONE ACETYLATION; IMMUNOFLUORESCENCE MICROSCOPY; LEUKEMIA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

ACETYLATION; ANTINEOPLASTIC AGENTS; CELL ADHESION; HL-60 CELLS; HUMANS; HYDROXAMIC ACIDS; K562 CELLS; LEUKEMIA; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEOME; TIME FACTORS;

EID: 84870391600     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.09.014     Document Type: Article

References (62)

1. Di Gennaro E., Bruzzese F., Caraglia M., Abruzzese A., Budillon A. Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids 2004, 26:435-441.
2. Peixoto P., Lansiaux A. Histone-deacetylases inhibitors: from TSA to SAHA. Bull Cancer 2006, 93:27-36.
3. Marks P.A., Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009, 107:600-608.
4. Adcock I.M. Histone deacetylase inhibitors as novel anti-inflammatory agents. Curr Opin Investig Drugs 2006, 7:966-973.
5. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
6. Kelly W.K., Marks P.A. Drug insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005, 2:150-157.
7. Gaymes T.J., Padua R.A., Pla M., Orr S., Omidvar N., Chomienne C., et al. Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?. Mol Cancer Res 2006, 4:563-573.
8. Fischer J.J., Michaelis S., Schrey A.K., Diehl A., Graebner O.Y., Ungewiss J., et al. SAHA Capture Compound-a novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders. Proteomics 2011, 11:4096-4104.
9. Tong A., Zhang H., Li Z., Gou L., Wang Z., Wei H., et al. Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid. Cancer Chemother Pharmacol 2008, 61:791-802.
10. He J., Huang C., Tong A., Chen B., Zeng Z., Zhang P., et al. Proteomic analysis of cervical cancer cells treated with suberonylanilide hydroxamic acid. J Biosci 2008, 33:715-721.
11. Colussi C., Banfi C., Brioschi M., Tremoli E., Straino S., Spallotta F., et al. Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment. Proteomics Clin Appl 2010, 4:71-83.
12. Li J., Liu R., Lei Y., Wang K., Lau Q.C., Xie N., et al. Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells. Autophagy 2010, 6:711-724.
13. Kuzelova K., Pluskalova M., Brodska B., Otevrelova P., Elknerova K., Grebenova D., et al. Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin. J Cell Biochem 2010, 109:184-195.
14. Nimmanapalli R., Fuino L., Bali P., Gasparetto M., Glozak M., Tao J., et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003, 63:5126-5135.
15. Fiskus W., Pranpat M., Balasis M., Bali P., Estrella V., Kumaraswamy S., et al. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 2006, 12:5869-5878.
16. Li L., Wang L., Li L., Wang Z., Ho Y., McDonald T., et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012, 21:266-281.
17. Konig H., Holtz M., Modi H., Manley P., Holyoake T.L., Forman S.J., et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 2008, 22:748-755.
18. Weisberg E., Wright R.D., McMillin D.W., Mitsiades C., Ray A., Barrett R., et al. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther 2008, 7:1121-1129.
19. Hu Y., Swerdlow S., Duffy T.M., Weinmann R., Lee F.Y., Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A 2006, 103:16870-16875.
20. Geay J.F., Buet D., Zhang Y., Foudi A., Jarrier P., Berthebaud M., et al. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res 2005, 65:2676-2683.
21. Salgia R., Quackenbush E., Lin J., Souchkova N., Sattler M., Ewaniuk D.S., et al. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood 1999, 94:4233-4246.
22. Wozniak M.A., Modzelewska K., Kwong L., Keely P.J. Focal adhesion regulation of cell behavior. Biochim Biophys Acta 2004, 1692:103-119.
23. Goetz J.G. Bidirectional control of the inner dynamics of focal adhesions promotes cell migration. Cell Adh Migr 2009, 3:185-190.
24. Dovas A., Cox D. Signaling networks regulating leukocyte podosome dynamics and function. Cell Signal 2011, 23:1225-1234.
25. Krutzik P.O., Nolan G.P. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 2003, 55:61-70.
26. Kuzelova K., Grebenova D., Brodska B. Dose-dependent effects of the caspase inhibitor Q-VD-OPh on different apoptosis-related processes. J Cell Biochem 2011, 112:3334-3342.
27. Kuzelova K., Pluskalova M., Grebenova D., Pavlaskova K., Halada P., Hrkal Z. Changes in cell adhesivity and cytoskeleton-related proteins during imatinib-induced apoptosis of leukemic JURL-MK1 cells. J Cell Biochem 2010, 111:1413-1425.
28. Birkenfeld J., Betz H., Roth D. Identification of cofilin and LIM-domain-containing protein kinase 1 as novel interaction partners of 14-3-3 zeta. Biochem J 2003, 369:45-54.
29. Gohla A., Bokoch G.M. 14-3-3 regulates actin dynamics by stabilizing phosphorylated cofilin. Curr Biol 2002, 12:1704-1710.
30. Liang S., Yu Y., Yang P., Gu S., Xue Y., Chen X. Analysis of the protein complex associated with 14-3-3 epsilon by a deuterated-leucine labeling quantitative proteomics strategy. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:627-634.
31. Dokmanovic M., Marks P.A. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005, 96:293-304.
32. Li N., Jiang P., Du W., Wu Z., Li C., Qiao M., et al. Siva1 suppresses epithelial-mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules. Proc Natl Acad Sci U S A 2011, 108:12851-12856.
33. O'Connor O.A., Heaney M.L., Schwartz L., Richardson S., Willim R., MacGregor-Cortelli B., et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006, 24:166-173.
34. Montes de Oca R., Lee K.K., Wilson K.L. Binding of barrier to autointegration factor (BAF) to histone H3 and selected linker histones including H1.1. J Biol Chem 2005, 280:42252-42262.
35. Naldi M., Calonghi N., Masotti L., Parolin C., Valente S., Mai A., et al. Histone post-translational modifications by HPLC-ESI-MS after HT29 cell treatment with histone deacetylase inhibitors. Proteomics 2009, 9:5437-5445.
36. Chua B.T., Volbracht C., Tan K.O., Li R., Yu V.C., Li P. Mitochondrial translocation of cofilin is an early step in apoptosis induction. Nat Cell Biol 2003, 5:1083-1089.
37. Mannherz H.G., Gonsior S.M., Gremm D., Wu X., Pope B.J., Weeds A.G. Activated cofilin colocalises with Arp2/3 complex in apoptotic blebs during programmed cell death. Eur J Cell Biol 2005, 84:503-515.
38. Wang C., Zhou G.L., Vedantam S., Li P., Field J. Mitochondrial shuttling of CAP1 promotes actin- and cofilin-dependent apoptosis. J Cell Sci 2008, 121:2913-2920.
39. Ivaska J., Pallari H.M., Nevo J., Eriksson J.E. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res 2007, 313:2050-2062.
40. Burgstaller G., Gregor M., Winter L., Wiche G. Keeping the vimentin network under control: cell-matrix adhesion-associated plectin 1f affects cell shape and polarity of fibroblasts. Mol Biol Cell 2010, 21:3362-3375.
41. Kim H., Nakamura F., Lee W., Hong C., Perez-Sala D., McCulloch C.A. Regulation of cell adhesion to collagen via beta1 integrins is dependent on interactions of filamin A with vimentin and protein kinase C epsilon. Exp Cell Res 2010, 316:1829-1844.
42. Nieminen M., Henttinen T., Merinen M., Marttila-Ichihara F., Eriksson J.E., Jalkanen S. Vimentin function in lymphocyte adhesion and transcellular migration. Nat Cell Biol 2006, 8:156-162.
43. Pan Y.R., Chen C.L., Chen H.C. FAK is required for the assembly of podosome rosettes. J Cell Biol 2011, 195:113-129.
44. Mendez M.G., Kojima S., Goldman R.D. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J 2010, 24:1838-1851.
45. Zhu Q.S., Rosenblatt K., Huang K.L., Lahat G., Brobey R., Bolshakov S., et al. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene 2011, 30:457-470.
46. Byun Y., Chen F., Chang R., Trivedi M., Green K.J., Cryns V.L. Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ 2001, 8:443-450.
47. Muller K., Dulku S., Hardwick S.J., Skepper J.N., Mitchinson M.J. Changes in vimentin in human macrophages during apoptosis induced by oxidised low density lipoprotein. Atherosclerosis 2001, 156:133-144.
48. Lahat G., Zhu Q.S., Huang K.L., Wang S., Bolshakov S., Liu J., et al. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One 2010, 5:e10105.
49. Dingova H., Fukalova J., Maninova M., Philimonenko V.V., Hozak P. Ultrastructural localization of actin and actin-binding proteins in the nucleus. Histochem Cell Biol 2009, 131:425-434.
50. Melhem R.F., Zhu X.X., Hailat N., Strahler J.R., Hanash S.M. Characterization of the gene for a proliferation-related phosphoprotein (oncoprotein 18) expressed in high amounts in acute leukemia. J Biol Chem 1991, 266:17747-17753.
51. Rubin C.I., French D.L., Atweh G.F. Stathmin expression and megakaryocyte differentiation: a potential role in polyploidy. Exp Hematol 2003, 31:389-397.
52. Larsson N., Segerman B., Gradin H.M., Wandzioch E., Cassimeris L., Gullberg M. Mutations of oncoprotein 18/stathmin identify tubulin-directed regulatory activities distinct from tubulin association. Mol Cell Biol 1999, 19:2242-2250.
53. Tran A.D., Marmo T.P., Salam A.A., Che S., Finkelstein E., Kabarriti R., et al. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci 2007, 120:1469-1479.
54. Matsuyama A., Shimazu T., Sumida Y., Saito A., Yoshimatsu Y., Seigneurin-Berny D., et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 2002, 21:6820-6831.
55. Zhang X., Yuan Z., Zhang Y., Yong S., Salas-Burgos A., Koomen J., et al. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 2007, 27:197-213.
56. Flaiz C., Chernoff J., Ammoun S., Peterson J.R., Hanemann C.O. PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. Exp Neurol 2009, 218:137-144.
57. Arias-Romero L.E., Chernoff J. A tale of two Paks. Biol Cell 2008, 100:97-108.
58. Noma H., Kato T., Fujita H., Kitagawa M., Yamano T., Kitagawa S. Calpain inhibition induces activation of the distinct signalling pathways and cell migration in human monocytes. Immunology 2009, 128:e487-e496.
59. Wang H., Zeng X., Fan Z., Lim B. RhoH plays distinct roles in T-cell migrations induced by different doses of SDF1 alpha. Cell Signal 2010, 22:1022-1032.
60. Yang L., Wang L., Geiger H., Cancelas J.A., Mo J., Zheng Y. Rho GTPase Cdc42 coordinates hematopoietic stem cell quiescence and niche interaction in the bone marrow. Proc Natl Acad Sci U S A 2007, 104:5091-5096.
61. Deacon S.W., Beeser A., Fukui J.A., Rennefahrt U.E., Myers C., Chernoff J., et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 2008, 15:322-331.
62. Viaud J., Peterson J.R. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol Cancer Ther 2009, 8:2559-2565.